Trial | NCT00955630  Report issue

Official Title

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    ranibizumab ...

  • Study Participants

    20
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
Patients will be evaluated monthly for one year.

Participants will be assigned to one of two groups:

Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection throughout the remainder of the study Group B will receive injections of ranibizumab on an as needed basis throughout the study

You cannot take part in this study if:

You are pregnant or intending to become pregnant in the next 12 months or are nursing an infant
You are under the age of 18
Study Started
Aug 31
2009
Primary Completion
Aug 31
2010
Anticipated
Last Update
Aug 10
2009
Estimate

Drug ranibizumab

prn injections of ranibizumab throughout the study

  • Other names: Lucentis

Drug ranibizumab

3 monthly injections of ranibizumab followed by prn injections for the remainder of the study

  • Other names: Lucentis

Monthly injections Active Comparator

3 monthly injections of ranibizumab followed by prn injections

PRN injections Active Comparator

injections of ranibizumab on a prn basis from the start of the study

Criteria 

Inclusion Criteria:

age 18 or over
active choroidal neovascularization secondary to ocular histoplasmosis
Visual acuity between 20/25 and 20/400

Exclusion Criteria:

pregnancy or intent to become pregnant within the next 12 months
nursing an infant
premenopausal women not using contraception
prior treatment with subfoveal thermal laser
allergy to sodium fluorescein simultaneous participation in another investigation or trial
No Results Posted